Methoxetamine, a novel psychoactive substance with serious adverse pharmacological effects: A review of case reports and preclinical findings

Behavioural Pharmacology

Volumn 27, Issue 6, 2016, Pages 489-496

  Zanda, Mary T ^a   Fadda, Paola ^a   Chiamulera, Cristiano ^c   Fratta, Walter ^a   Fattore, Liana ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

intoxication; ketamine; legal highs; methoxetamine; novel psychoactive substances

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN; METHOXETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PSYCHOTROPIC AGENT; UNCLASSIFIED DRUG; 2-(3-METHOXYPHENYL)-2-(ETHYLAMINO)CYCLOHEXANONE; CYCLOHEXANONE DERIVATIVE; CYCLOHEXYLAMINE DERIVATIVE; DOPAMINE; STREET DRUG;

AGE; AGGRESSION; AGITATION; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; CATATONIA; CAUCASIAN; CEREBELLAR ATAXIA; CONFUSION; DELIRIUM; DIARRHEA; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG ABUSE; DRUG INTOXICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSARTHRIA; FEAR; FIRING RATE; GENDER; HALLUCINATION; HOME ENVIRONMENT; HUMAN; HYPERTENSION; INTERNET; LIQUID; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOTOR DYSFUNCTION; MYDRIASIS; NAUSEA; NONHUMAN; NUCLEUS ACCUMBENS SHELL; NYSTAGMUS; PLACE PREFERENCE; RESPIRATION DEPRESSION; RESTLESSNESS; REVIEW; SELF REPORT; SIDE EFFECT; TACHYCARDIA; UNITED KINGDOM; VENTRAL TEGMENTUM; VOMITING; ANIMAL; COMPLICATION; DRUG DEPENDENCE; METABOLISM; TIME FACTOR;

ANIMALS; CYCLOHEXANONES; CYCLOHEXYLAMINES; DOPAMINE; HUMANS; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

EID: 84964632272     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000241     Document Type: Review

References (65)

1. Abe E, Ricard F, Darrouzain F, Alvarez JC (2013). An automated method for measurement of methoxetamine in human plasma by use of turbulent flow online extraction coupled with liquid chromatography and mass spectrometric detection. Anal Bioanal Chem 405:239-245.
2. Adamowicz P, Zuba D (2015). Fatal intoxication with methoxetamine. J Forensic Sci 60 (Suppl 1):S264-S268.
3. Advisory Council on the Misuse of Drugs (ACMD). Methoxetamine report. 2012. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/119087/methoxetamine2012.pdf. [Accessed 13 October Table 1 2015].
4. Ault DT, Werling LL (1999). Phencyclidine and dizocilpine modulate dopamine release from rat nucleus accumbens via sigma receptors. Eur J Pharmacol 386:145-153.
5. Balster RL, Bigelow GE (2003). Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend 70 (Suppl):13-40.
6. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000). Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354.
7. Botanas CJ, de la Peña JB, Dela Peña IJ, Tampus R, Yoon R, Kim HJ, et al. (2015). Methoxetamine, a ketamine derivative, produced conditioned place preference and was self-administered by rats: evidence of its abuse potential. Pharmacol Biochem Behav 133:31-36.
8. Caffino L, Di Chio M, Giannotti G, Venniro M, Mutti A, Padovani L, et al. (2016). The modulation of BDNF expression and signalling dissects the antidepressant from the reinforcing properties of ketamine: Effects of single infusion vs. chronic self-administration in rats. Pharmacol Res 104:22-30.
9. Chiamulera C, Armani F, Mutti A, Fattore L (2016). The ketamine analogue methoxetamine generalizes to ketamine discriminative stimulus in rats. Behav Pharmacol 27:204-210.
10. Chiappini S, Claridge H, Corkery JM, Goodair C, Loi B, Schifano F (2015). Methoxetamine-related deaths in the UK: an overview. Hum Psychopharmacol 30:244-248.
11. Coppola M, Mondola R (2012). Methoxetamine: from drug of abuse to rapidacting antidepressant. Med Hypotheses 79:504-507.
12. Corazza O, Schifano F, Simonato P, Fergus S, Assi S, Stair J, et al. (2012). Phenomenon of new drugs on the internet: the case of ketamine derivative methoxetamine. Hum Psychopharmacol 27:145-149.
13. Corazza O, Assi S, Schifano F (2013). From 'special K' to 'special M': the evolution of the recreational use of ketamine and methoxetamine. CNS Neurosci Ther 19:454-460.
14. Craig CL, Loeffler GH (2014). The ketamine analog methoxetamine: a new designer drug to threaten military readiness. Mil Med 179:1149-1157.
15. Dargan PI, Tang HC, Liang W, Wood DM, Yew DT (2014). Three months of methoxetamine administration is associated with significant bladder and renal toxicity in mice. Clin Toxicol (Phila) 52:176-180.
16. Davidson C, Schifano F (2016). The potential utility of some legal highs in CNS disorders. Prog Neuropsychopharmacol Biol Psychiatry 64:267-274.
17. Davidson C, Hashemi G, Gant A, Fergus S, Benha C, Lione L (2014). Effects of methoxetamine in rat bladder and nucleus accumbens brain tissue. Res Adv Psychiatry 1:39.
18. De Paoli G, Brandt SD, Wallach J, Archer RP, Pounder DJ (2013). From the street to the laboratory: analytical profiles of methoxetamine, 3-methoxyeticyclidine and 3-methoxyphencyclidine and their determination in three biological matrices. J Anal Toxicol 37:277-283.
19. Duman RS, Monteggia LM (2006). A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59:1116-1127.
20. Elian AA, Hackett J (2014). A polydrug intoxication involving methoxetamine in a drugs and driving case. J Forensic Sci 59:854-858.
21. Elie MP, Elie LE, Baron MG (2013). Keeping pace with NPS releases: fast GC-MS screening of legal high products. Drug Test Anal 5:281-290.
22. EMCDDA (2013). Methoxetamine. EMCDDA-Europol Joint Report on a new psychoactive substance: methoxetamine (2-(3-methoxyphenyl)-2-(ethyl amino) cyclohexanone). Available at: http://www.emcdda.europa.eu/attache ments.cfm/att-222602-EN-TDAS14004ENN-1.pdf. [Accessed 13 October 2015].
23. EMCDDA (2015). European drug reports. Available at: http://www.emcdda. europa.eu/edr2015. [Accessed 19 October 2015].
24. Erhardt S, Engberg G (2002). Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. Acta Physiol Scand 175:45-53.
25. Erowid (2011). Available at: https://www.erowid.org/. [Accessed 13 October 2015].
26. Fattore L, Fratta W (2011). Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 5:60.
27. Halberstadt AL, Slepak N, Hyun J, Buell MR, Powell SB (2016). The novel ketamine analog methoxetamine produces dissociative-like behavioral effects in rodents. Psychopharmacology (Berl) 233:1215-1225.
28. Hill SL, Harbon SC, Coulson J, Cooper GA, Jackson G, Lupton DJ, et al. (2014). Methoxetamine toxicity reported to the national poisons information service: clinical characteristics and patterns of enquiries (including the period of the introduction of the UK's first temporary class drug order). Emerg Med J 31:45-47.
29. Hofer KE, Grager B, Müller DM, Rauber-Lüthy C, Kupferschmidt H, Rentsch KM, Ceschi A (2012). Ketamine-like effects after recreational use of methoxetamine. Ann Emerg Med 60:97-99.
30. Hydzik P, Szkolnicka B, Gomólka E (2013). Children and adolescents toxic exposure in 2010-2012-data of Poison Information Centre and Laboratory of Analytical Toxicology and Drug Monitoring Jagiellonian University Medical College. Przegl Lek 70:528-532.
31. Home Office (2013). Home Office, 2013. Available at: https://www.gov.uk/gov ernment/uploads/system/uploads/attachment-data/file/170610/offencerecording-codes.pdf. [Accessed 9 July 2014].
32. Imbert L, Boucher A, Delhome G, Cueto T, Boudinaud M, Maublanc J, et al. (2014). Analytical findings of an acute intoxication after inhalation of methoxetamine. J Anal Toxicol 38:410-415.
33. Karinen R, Tuv SS, Rogde S, Peres MD, Johansen U, Frost J, et al. (2014). Lethal poisonings with AH-7921 in combination with other substances. Forensic Sci Int 244:21-24.
34. Kinyua J, Covaci A, Maho W, McCall AK, Neels H, van Nuijs AL (2015). Sewagebased epidemiology in monitoring the use of new psychoactive substances: validation and application of an analytical method using LC-MS/MS. Drug Test Anal 7:812-818.
35. Kjellgren A, Jonsson K (2013). Methoxetamine (MXE) - a phenomenological study of experiences induced by a 'legal high' from the internet. J Psychoactive Drugs 45:276-286.
36. Krishnan V, Nestler EJ (2008). The molecular neurobiology of depression. Nature 455:894-902.
37. Lawn W, Borschmann R, Cottrell A, Winstock A (2016). Methoxetamine: prevalence of use in the USA and UK and associated urinary problems. J Subst Use 21:115-120.
38. Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA Jr (2009). Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 123:143-150.
39. Masuzawa M, Nakao S, Miyamoto E, Yamada M, Murao K, Nishi K, Shingu K (2003). Pentobarbital inhibits ketamine-induced dopamine release in the rat nucleus accumbens: a microdialysis study. Anesth Analg 96: 148-152.
40. Menzies EL, Hudson SC, Dargan PI, Parkin MC, Wood DM, Kicman AT (2014). Characterizing metabolites and potential metabolic pathways for the novel psychoactive substance methoxetamine. Drug Test Anal 6:506-515.
41. Meyer MR, Bach M, Welter J, Bovens M, Turcant A, Maurer HH (2013). Ketaminederived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn. Anal Bioanal Chem 405:6307-6321.
42. Morris H (2011). Interview with a ketamine chemist: Or to be more precise, an arylcyclohexylamine chemist. Vice Magazine. Available at: www.vice.com/read/interview-with-ketaminechemist-704-v18n2. [Accessed 11 October 2014].
43. Morris H, Wallach J (2014). From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Test Anal 6:614-632.
44. Mutti A, Aroni S, Fadda P, Padovani L, Mancini L, Collu R, et al. (2016). The ketamine-like compound methoxetamine substitutes for ketamine in the selfadministration paradigm and enhances mesolimbic dopaminergic transmission. Psychopharmacology (Berl) (in press).
45. O'Connor EC, Chapman K, Butler P, Mead AN (2011). The predictive validity of the rat self-administration model for abuse liability. Neurosci Biobehav Rev 35:912-938.
46. Rosenbaum CD, Carrero SP, Babu KM (2012). Here today, gone tomorrow⋯ and back again? A review of herbal marijuana alternatives (K2, spice), synthetic cathinones (bath salts), kratom, salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 8:15-32.
47. Roth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, Iversen L (2013). The ketamine analogue methoxetamine and 3-and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS One 8:e59334.
48. Schifano F, Orsolini L, Duccio Papanti G, Corkery JM (2015). Novel psychoactive substances of interest for psychiatry. World Psychiatry 14:15-26.
49. Seely KA, Lapoint J, Moran JH, Fattore L (2012). Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 39:234-243.
50. Sein Anand J, Wiergowski M, Barwina M, Kaletha K (2012). Accidental intoxication with high dose of methoxetamine (MXE) - a case report. Przegl Lek 69:609-610.
51. Shields JE, Dargan PI, Wood DM, Puchnarewicz M, Davies S, Waring WS (2012). Methoxetamine associated reversible cerebellar toxicity: three cases with analytical confirmation. Clin Toxicol (Phila) 50:438-440.
52. Skolnick P (1999). Antidepressants for the new millennium. Eur J Pharmacol 375 (1-3):31-40.
53. Swedberg MDB, Giarola A (2015). Drug discrimination: use in preclinical assessment of abuse liability. In: Markgraf CG, Hudzik TJ, Compton DR, editors. Nonclinical Assessment of Abuse Potential for New Pharmaceuticals. London: Academic Press. pp. 129-149.
54. Tedesco V, Ravagnani C, Bertoglio D, Chiamulera C (2013). Acute ketamineinduced neuroplasticity: ribosomal protein S6 phosphorylation expression in drug addiction-related rat brain areas. Neuroreport 24:388-393.
55. UNODC (2015). Word drug report. Available at: https://www.unodc.org/docu ments/wdr2015/World-Drug-Report-2015.pdf. [Accessed 19 October 2015].
56. Ward J, Rhyee S, Plansky J, Boyer E (2011). Methoxetamine: a novel ketamine analog and growing health-care concern. Clin Toxicol (Phila) 49:874-875.
57. Westwell AD, Hutchings A, Caldicott DG (2013). The identification and chemical characterization of a new arylcyclohexylamine, methoxetamine, using a novel emergency department toxicosurveillance tool. Drug Test Anal 5:203-207.
58. WHO (2015). Methoxetamine (MXE) critical review report 37th ECDD Agenda item 5.9. Available at: http://www.who.int/medicines/access/controlled-sub stances/5.9-Methoxetamine-CRev.pdf. [Accessed 13 October 2015].
59. Wiergowski M, Anand JS, Krzyzanowski M, Jankowski Z (2014). Acute methoxetamine and amphetamine poisoning with fatal outcome: a case report. Int J Occup Med Environ Health 27:683-690.
60. Wikström M, Thelander G, Dahlgren M, Kronstrand R (2013). An accidental fatal intoxication with methoxetamine. J Anal Toxicol 37:43-46.
61. Winstock AR, Lawn W, Deluca P, Borschmann R (2016). Methoxetamine: an early report on the motivations for use, effect profile and prevalence of use in a UK clubbing sample. Drug Alcohol Rev 35:212-217.
62. Wood DM, Hunter L, Measham F, Dargan PI (2012a). Limited use of novel psychoactive substances in South London nightclubs. QJM 105:959-964.
63. Wood DM, Davies S, Puchnarewicz M, Johnston A, Dargan PI (2012b). Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. Eur J Clin Pharmacol 68:853-856.
64. Zawilska JB (2014). Methoxetamine - a novel recreational drug with potent hallucinogenic properties. Toxicol Lett 230:402-407.
65. Zawilska JB, Andrzejczak D (2015). Next generation of novel psychoactive substances on the horizon-A complex problem to face. Drug Alcohol Depend 157:1-17